Although SFN expression was not significantly correlated with poor overall survival, the higher expression of SFN in all patients with ovarian cancers is significantly correlated with the better progression-free survival (PFS) and worse postprogression survival (PPS) (P<0.05). Here, SFN is linked to ovarian carcinoma.